香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告不會直接或間接於或向美國（包括美國的領土及屬地、任何州以及哥倫比 亞特區）派發。本公告並不構成或組成在美國境內購買或認購證券的任何要約或 招攬的一部分。本公告所述認購股份並無亦不會根據一九三三年美國證券法（「證 券法」）登記。 認購股份不得在美國境內或向美籍人士（定義見證券法S規例）或以其名義或為其 利益提呈發售或出售，惟獲豁免遵守證券法登記規定者除外。證券將不會於美國 公開發售。 由於認購事項須待認購協議所載之先決條件達成後，方告完成，故認購事項未必 會進行。本公司股東及潛在投資者於買賣股份時務請審慎行事。 承董事會命 網址：https://290.com.hk （股份代號：290） 有關 新訂根據一般授權認購新股份之 補充公告 茲提述國富量子創新有限公司（「本公司」）日期為二零二五年九月四日有關（其中 包括）認購事項之公告（ ...

Group 1 - The core point of the article is that Huayang has informed the company of his intention to devote more time to personal endeavors and will not seek re-election at the shareholders' annual meeting [1] - Huayang will officially resign as a non-executive director at the conclusion of the postponed shareholders' annual meeting [1]

Core Viewpoint - Guofu Quantum (00290) announced that Mr. Huayang has resigned as a non-executive director following the conclusion of the postponed annual general meeting [1] Company Summary - Guofu Quantum has undergone a change in its board structure with the resignation of a key non-executive director [1]

智通财经APP讯，国富量子(00290)发布公告，华旸先生已于经改期股东周年大会结束时退任非执行董 事。 ...

網址：https://290.com.hk （股份代號：290） GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 董事名單及彼等的角色與職能 國富量子創新有限公司的董事會（「董事會」）成員載列如下： 執行董事 孫青女士 非執行董事 聶日明博士 李春光先生 獨立非執行董事 陳健生先生 （主席） 趙公直先生 雷美嘉女士 梁金祥博士 董事會已設立下列三個董事委員會。下表載列若干董事會成員於此等董事委員會 中所擔任的職位： | | 董事委員會 審核委員會 | 提名委員會 | 薪酬委員會 | | --- | --- | --- | --- | | 董事會 | | | | | 孫青女士 | | M | M | | 聶日明博士 | | | | | 李春光先生 | | | | | 陳健生先生 | M | C | M | | 趙公直先生 | C | M | C | | 雷美嘉女士 | M | M | M | | 梁金祥博士 | M | M | M | 附註： C ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 網址：https://290.com.hk （股份代號：290） (1)於二零二五年九月十九日舉行之經改期股東週年大會 投票表決結果 | | | 票數 | | | | --- | --- | --- | --- | --- | | | 普通決議案* | （概約百分比） | | 投票總數 | | | | 贊成 | 反對 | | | 1. | 接受、考慮及採納截至二零二五年三月 | 2,958,252,835 | 0 | 2,958,252,835 | | | 三十一日止年度之經審核綜合財務報表 | (100%) | (0%) | | | | 及本公司董事（「董事」）會報告書與本公 | | | ...

有關 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 網址：https://290.com.hk （股份代號：290） 自願性公告 與金涌投資有限公司之戰略合作 之補充公告 茲提述國富量子創新有限公司（「本公司」）日期為二零二五年八月二十六日有關（其 中包括）戰略合作之自願性公告（「該公告」）。除另有界定外，本公告所用詞彙與 該公告所界定者具有相同涵義。 本公司謹此向本公司股東及潛在投資者提供有關戰略合作之補充資料。 戰略合作 — RWA代幣化產品及RWA項目 鑒於本公司與金涌投資簽署之戰略合作備忘錄僅構成合作之指示性框架，擬開展 之RWA 代幣化產品及RWA 項目目前仍在考量及評估中。於本公告日期，該等產品 及項目可能包括符合以下條件的 ...

Core Viewpoint - Huajian Medical (01931) is acquiring approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of its total issued share capital, for about HKD 3.142 billion, positioning Huajian Medical as the largest single shareholder of Guofu Quantum [1] Group 1 - The acquisition is a key move for Huajian Medical to advance its strategy of establishing a Real World Asset (RWA) tokenization exchange [1] - Huajian Medical possesses extensive resources in the medical industry, while its exchange offers a technology platform and trading venue for asset tokenization [1] - Guofu Quantum has strong capabilities in financial technology, providing financial licensing resources, digital asset issuance and trading capabilities, as well as expertise in quantum technology [1] Group 2 - Huajian Medical can leverage Guofu Quantum's 22.5% stake in Southern Dongying to collaboratively build a blockchain and financial technology-centric on-chain financial ecosystem [1] - This platform aims to integrate compliant digital architecture with traditional asset forms, promoting asset tokenization, fragmentation, and cross-border flow [1] - The initiative is focused on creating a new type of financial infrastructure [1]

Core Viewpoint - Huajian Medical (01931) plans to acquire approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of its total issued share capital, for about HKD 3.142 billion, making Huajian the largest single shareholder of Guofu Quantum after the transaction [1] Group 1: Acquisition Details - The acquisition price for Guofu Quantum shares is approximately HKD 3.142 billion [1] - After the acquisition, Huajian Medical will hold 20.31% of Guofu Quantum's total issued share capital [1] Group 2: Strategic Importance - This acquisition is a key move for Huajian Medical to advance its strategy of establishing a Real World Asset (RWA) tokenization exchange [1] - Huajian Medical possesses extensive resources in the medical industry, while Guofu Quantum has strong capabilities in financial technology [1] Group 3: Resource Sharing and Synergy - Huajian Medical can leverage Guofu Quantum's 22.5% stake in Southern Dongying to collaboratively build a blockchain and financial technology-centric on-chain financial ecosystem [1] - The new platform aims to integrate compliant digital architecture with traditional asset forms, promoting asset tokenization, fragmentation, and cross-border flow [1]

Core Viewpoint - The company has terminated the original subscription agreement due to unmet conditions and current market conditions, and has entered into a new subscription agreement with 11 subscribers to issue 745 million shares at a discounted price [1] Group 1: Subscription Agreement Details - The original subscription agreement will no longer proceed, and both parties will not seek compensation from each other [1] - A new subscription agreement was signed on September 4, 2025, for a total of 745 million shares, representing approximately 7.57% of the enlarged total share capital [1] - The subscription price is set at HKD 1.78 per share, which is about 16.43% lower than the closing price of HKD 2.13 on September 4 [1] Group 2: Financial Implications - The new subscription is expected to raise approximately HKD 1.3264 billion in total funds, with a net amount of about HKD 1.3214 billion [1]